PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more
Pam Kusar thought she had “GHD gut.” Or worse.
Anyone who’s done GHD sit-ups after a reprieve from the movement knows the feeling—getting out of bed, sneezing, laughing, crying all induce pain, if you’ve done more reps than you should … Read more
Researchers at the UC San Diego School of Medicine were awarded $5.8 million Thursday to develop an immunotherapy that would target certain cancer stem cells.
The grant from the California Institute for Regenerative Medicine’s Independent Citizens Oversight Committee addresses cancers … Read more
The protein CA125, which is commonly expressed on the surface of ovarian cancer cells and is secreted into the bloodstream, was found to block the activity of investigational drug farletuzumab. Farletuzumab is currently in clinical development for the treatment of … Read more
Mutations in the BRCA gene correspond to a higher lifetime risk of developing breast and ovarian cancers, and many women who carry these mutations consider undergoing mastectomy or removal of the ovaries and fallopian tubes as preventive measures.
But for
… Read moreToward the end of the great adventure movie “A High Wind in Jamaica,” a gang of pirates is sentenced to hang for a murder they didn’t commit.
“I don’t want to die innocent!” a crewman cries out to his captaI … Read more
For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are … Read more
Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer. A multi-centre clinical trial has demonstrated that CT Perfusion, which measures blood … Read more
British biotech company Angle has unveiled the trial results of a potential breakthrough blood test for diagnosing ovarian cancer.
The test could lead to quicker diagnosis and referrals for women with malignant tumours to specialist surgeons.
Angle, an AIM-listed liquid … Read more
With 20,000 diagnoses each year, ovarian cancer is the ninth most common cancer and fifth leading cause of cancer death among women in the United States. So many women die from ovarian cancer because it often goes undetected until it … Read more
A new study that followed 10,000 women provides more accurate, age-related estimates of the risk of developing breast and ovarian cancer in carriers of mutations of the BRCA1 and BRCA2 genes. It also suggests that family history and the location … Read more
A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.
Researchers believe the drug, which mimics the action of folic acid to enter … Read more
The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more
With 38,000 oncologists converging on the sprawling McCormick Place for the annual meeting of the American Society of Clinical Oncology, the halls in the convention center are as crowded as Manhattan sidewalks at Christmastime. Watch out or you’ll get run … Read more
By: Annette McElhiney
As an avid reader of any and all material about cancer, my attention was grabbed by the article, “Hope and Hype Around Cancer Immunotherapy.”
Most of us are aware of the excitement currently generated by … Read more
By: Hillary Theakston, Executive Director of The Clearity Foundation
In May, for the first time, the U.S. Food and Drug Administration approved a cancer drug for patients whose tumors are defined by a specific genetic feature (biomarker), rather than by … Read more
The introduction of PARP inhibitors revolutionized the treatment of ovarian cancer, providing much-needed therapeutic options. However, clinical challenges remain as many patients are not candidates for PARP inhibitors and responses are often short-lived. Furthermore, biomarkers have not been established to … Read more
Immunotherapy treatments for cancer are having a moment.
